Digistain® reposted this
Revolutionising Cancer Diagnostics: Can Digistain® Secure the Reimbursement It Deserves? In the battle against #cancer, timely and precise diagnosis is everything. At the forefront of this revolution, Digistain a breakthrough in infrared spectroscopy offers #pathologists a new lens to decode #tumour biochemistry with unprecedented clarity and speed. Imagine assessing a tumour’s molecular “wiring” directly in a lab, slashing wait times and costs by a staggering 75% compared to traditional molecular tests. That’s what Digistain is enabling, by giving oncologists a powerful, low-cost tool to help prevent unnecessary chemotherapy while sparing patients the brutal side effects of overtreatment. Yet the journey towards reimbursement isn’t straightforward. For all its promise, Digistain faces an uphill challenge in entering healthcare systems traditionally bound to existing molecular diagnostics like Oncotype DX. These incumbents are deeply rooted in clinical practice and backed by extensive data, creating high hurdles for new technologies like Digistain to gain reimbursement approval. So, what’s different with Digistain? The science of infrared spectroscopy is pivotal. Unlike conventional tests, Digistain uses infrared light to reveal molecular markers that tell us about a tumour’s aggressiveness and potential for recurrence. By measuring aneuploidy—an imbalance in chromosome numbers in tumour cells—Digistain quantifies the DNA-to-protein ratio, offering a new prognostic score that rivals established methods in accuracy while cutting down costs significantly. This shift from subjective visual grading to objective molecular analysis could mean a profound shift in how we identify high-risk patients who truly need aggressive treatment. But to secure reimbursement, Digistain must prove its worth through rigorous real-world evidence, economic analyses, and alignment with value-based care models. As it scales to countries across the globe, including low- and middle-income settings where affordability is critical, Digistain’s path forward will depend on showcasing reliable outcomes in diverse patient populations. The potential of Digistain is enormous, but the healthcare land scape must accommodate this new wave of diagnostics to ensure patients everywhere receive the most personalised, effective cancer care possible. #CancerDiagnostics #Oncology #Digistain #InfraredSpectroscopy #HealthcareInnovation #MolecularDiagnostics #ReimbursementChallenge #RealWorldEvidence #PrecisionMedicine #ivd Cancer Research UK Science and Innovation Nick Wright Barts Cancer Institute (Queen Mary University of London) https://lnkd.in/e9M4gymn